Center for Scientific Review; Notice of Closed Meetings, 65388-65389 [E8-26103]
Download as PDF
<![CDATA[
65388
Federal Register / Vol. 73, No. 213 / Monday, November 3, 2008 / Notices
treatment. Frequency of Response:
Once. Affected Public: Individuals. Type
of Respondents: Individuals that had
previously participated in the Central
European Renal Cancer Case-Control
Study between 2001–2004 and
physician abstractors. The estimated
total annual burden hours requested is
296. The annualized cost to respondents
is estimated at $5174. There are no
additional capital costs, operating costs,
and/or maintenance costs to report.
TABLE 1—ESTIMATES OF ANNUAL BURDEN HOURS
Average
time per
response
(minutes/
hour)
Annual
burden
hours
Number of
respondents
Frequency
of response
Patients ............................................................................................................................
Families (NOK) ................................................................................................................
Physicians ........................................................................................................................
200
240
10
1
1
1
40/60
40/60
15/60
133.33
160.00
2.50
Totals ........................................................................................................................
450
....................
....................
295.83
Type of respondents
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Lee E. Moore, PhD,
MPH, Investigator/Epidemiologist,
Occupational and Environmental
Epidemiology Branch, Division of
Cancer Epidemiology and Genetics,
National Cancer Institute, NIH, DHHS,
Executive Plaza South, Room 8102,
6120 Executive Blvd., EPS–MSC 7240,
Bethesda, MD 20892–7270 or call nontoll-free number 301–496–6427 or email your request, including your
address to: moorele@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
sroberts on PROD1PC70 with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Aug<31>2005
16:58 Oct 31, 2008
Jkt 217001
Dated: October 24, 2008.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison Office,
National Institutes of Health.
[FR Doc. E8–26086 Filed 10–31–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Review of
KNOD and NAME Member Conflicts.
Date: November 20, 2008.
Time: 9 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Elisabeth Koss, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3152,
MSC 7770, Bethesda, MD 20892, (301) 435–
1721, kosse@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Shared
Instrumentation.
Date: November 20–21, 2008.
Time: 8 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: David Balasundaram, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189,
MSC 7840, Bethesda, MD 20892, 301–435–
1022, balasundaramd@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: AIDS and Related
Research Integrated Review Group AIDS
Molecular and Cellular Biology Study
Section.
Date: November 24, 2008.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Hotel, 2401 M Street,
NW., Washington, DC 20037.
Contact Person: Kenneth A. Roebuck, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5214,
MSC 7852, Bethesda, MD 20892, (301) 435–
1166, roebuckk@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Aging
Program Project Review.
Date: November 24–25, 2008.
Time: 8 a.m. to 8 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive,, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Seetha Bhagavan, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1126,
MSC 7846, Bethesda, MD 20892, (301) 435–
1121, bhagavas@csr.nih.gov.
E:\FR\FM\03NON1.SGM
03NON1
Federal Register / Vol. 73, No. 213 / Monday, November 3, 2008 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel A–START
Applications.
Date: November 25–26, 2008.
Time: 10 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jose H. Guerrier, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–435–
1137, guerriej@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel
Developmental Pharmacology.
Date: December 8, 2008.
Time: 12 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Janet M. Larkin, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1102,
MSC 7840, Bethesda, MD 20892, 310–435–
1026, larkinjacsr@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 27, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–26103 Filed 10–31–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
sroberts on PROD1PC70 with NOTICES
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Aug<31>2005
16:58 Oct 31, 2008
Jkt 217001
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Research Projects in Lung Failure.
Date: November 24, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Chang Sook Kim, PhD,
Scientific Review Officer, Review Branch,
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7190,
Bethesda, MD 20892, 301–435–0287,
carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: October 27, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–26098 Filed 10–31–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Fiscal Year (FY) 2009 Funding
Opportunity
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice of intent to award a
Single Source Grant to the Community
Anti-Drug Coalitions of America
(CADCA).
AGENCY:
SUMMARY: This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) intends to award
approximately $625,000 (total costs) per
year for up to five years to the
Community Anti-Drug Coalitions of
America (CADCA). This is not a formal
request for applications. Assistance will
be provided only to the Community
Anti-Drug Coalitions of America
(CADCA) based on the receipt of a
satisfactory application that is approved
by an independent review group.
Funding Opportunity Title: SP–09–
004.
Catalog Of Federal Domestic
Assistance (CFDA) Number: 93.243.
Authority: Sections 509, 516 and
520A of the Public Health Service Act,
as amended.
Justification: Only the Community
Anti-Drug Coalitions of America
(CADCA) is eligible to apply. The
Substance Abuse and Mental Health
PO 00000
Frm 00106
Fmt 4703
Sfmt 4703
65389
Services Administration (SAMHSA) is
seeking to award a single source grant
to the Community Anti-Drug Coalitions
of America (CADCA) to leverage
existing resources and conference
support to expand SAMHSA’s scope
and capacity to provide training and
technical assistance to a large number of
community leaders across the country
who are committed to substance abuse
prevention, substance abuse/addiction
treatment and recovery support, and
substance abuse/addiction-related
mental health issues.
The Community Anti-Drug Coalitions
of America (CADCA) is uniquely
qualified to carry out the activities of
this program because the purpose of the
program is to partner with a national
organization that has special expertise
and unique broad, national-level
experience in working with community
anti-drug coalitions. CADCA is the only
national organization that annually
provides training and technical
assistance through a national leadership
conference for thousands of members of
community coalitions dedicated to
preventing substance abuse. CADCA
currently is the sole organization that
plays a major role in helping to
strengthen and develop the nation’s
prevention infrastructure of anti-drug
coalitions in support of on-going
activities funded by SAMHSA’s priority
grant programs including: the Substance
Abuse Prevention and Treatment Block
Grant, the Strategic Prevention
Framework State Incentive Grant, and
the Drug Free Communities Support
Program. CADCA is the only identified
organization that currently meets this
experience level and national reach to
over 5,000 identified anti-drug
coalitions across the country. CADCA
has long been recognized in
communities as well as States
throughout the nation as the national
voice for the advocacy and technical
support of anti-drug coalitions. As such,
it is uniquely qualified and positioned
to carry out the requirements of this
announcement.
Contact: Shelly Hara, Substance
Abuse and Mental Health Services
Administration, 1 Choke Cherry Road,
Room 8–1081, Rockville, MD 20857;
telephone: (240) 276–2321; E-mail:
shelly.hara@samhsa.hhs.gov.
Toian Vaughn,
SAMHSA Committee Management Officer.
[FR Doc. E8–26102 Filed 10–31–08; 8:45 am]
BILLING CODE 4162–20–P
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 73, Number 213 (Monday, November 3, 2008)]
[Notices]
[Pages 65388-65389]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-26103]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Review of KNOD and NAME Member Conflicts.
Date: November 20, 2008.
Time: 9 a.m. to 12 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Elisabeth Koss, PhD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3152, MSC 7770, Bethesda, MD 20892, (301) 435-
1721, kosse@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel Shared Instrumentation.
Date: November 20-21, 2008.
Time: 8 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Balasundaram, PhD, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189, MSC 7840, Bethesda, MD
20892, 301-435-1022, balasundaramd@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: AIDS and Related Research Integrated Review
Group AIDS Molecular and Cellular Biology Study Section.
Date: November 24, 2008.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant applications.
Place: The Fairmont Hotel, 2401 M Street, NW., Washington, DC
20037.
Contact Person: Kenneth A. Roebuck, PhD, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5214, MSC 7852, Bethesda, MD
20892, (301) 435-1166, roebuckk@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel Aging Program Project Review.
Date: November 24-25, 2008.
Time: 8 a.m. to 8 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Seetha Bhagavan, PhD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 1126, MSC 7846, Bethesda, MD 20892, (301) 435-
1121, bhagavas@csr.nih.gov.
[[Page 65389]]
Name of Committee: Center for Scientific Review Special Emphasis
Panel A-START Applications.
Date: November 25-26, 2008.
Time: 10 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jose H. Guerrier, PhD, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD
20892, 301-435-1137, guerriej@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel Developmental Pharmacology.
Date: December 8, 2008.
Time: 12 p.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Janet M. Larkin, PhD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 1102, MSC 7840, Bethesda, MD 20892, 310-435-
1026, larkinjacsr@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: October 27, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-26103 Filed 10-31-08; 8:45 am]
BILLING CODE 4140-01-M
